Figure 6.

MLN8237 alone or in combination with CDDP effectively reduces resistant cell‐derived xenograft growth in vivo. MKN45 cell‐derived xenograft tumors (150–200 mm³ in size) were treated with CDDP (2.5 mg·kg⁻¹, once a week) alone, MLN8237 (40 mg·kg⁻¹, five times a week) alone, or with combination of CDDP and MLN8237 for 28 days, and tumor sizes were measured twice a week. (A,B) The data indicated that MLN8237 alone or in combination with CDDP has a significant antitumor activity against resistant MKN45 cell‐derived xenografts. (C) Tumor tissue lysates were subjected to western blot analysis of the indicated proteins. (D) IHC analysis of MKN45 cell‐derived xenografts showing Ki‐67 and cleaved caspase‐3 expressions in vivo. Relative integrated density indicates the quantification data of immunostaining intensities, which was calculated using image j software; **P < 0.01, ***P < 0.001.